Gyre Therapeutics to Present at Sidoti Virtual Investor Conference

Rhea-AI Summary

Gyre Therapeutics (Nasdaq: GYRE), a commercial-stage biotech company, has announced its participation in the upcoming Sidoti August Virtual Investor Conference. Han Ying, PhD, the company's CEO, will present a company overview on Thursday, August 15, 2024, at 10:45 a.m. ET (7:45 a.m. PT).

Gyre Therapeutics is known for its self-sustainable approach and focuses on developing treatments for various chronic organ diseases. Interested parties can register in advance for the presentation webcast. For those unable to attend live, a replay will be available on the Events and Presentations page of Gyre's website following the session.

News Market Reaction – GYRE

+2.67%

+2.67% Session move

In the trading session that priced this news, GYRE gained 2.67%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying, PhD, Chief Executive Officer, will be presenting a company overview at the Sidoti August Virtual Investor Conference on Thursday, August 15, 2024, at 10:45 a.m. ET (7:45 a.m. PT).

To register in advance for the presentation webcast, sign up here.

A webcast replay will be accessible following the live session on the Events and Presentations page of Gyre’s website.

About Gyre Therapeutics

Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, with a primary focus on the development and commercialization of F351 (Hydronidone) for the treatment of NASH-associated fibrosis in the U.S. Gyre’s development strategy for F351 in NASH is based on the company’s experience in NASH rodent model mechanistic studies and CHB-induced liver fibrosis clinical studies. Gyre is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230.

For Investors:

Stephen Jasper

stephen@gilmartinir.com

FAQ

When is Gyre Therapeutics (GYRE) presenting at the Sidoti Virtual Investor Conference?

Gyre Therapeutics (GYRE) is presenting at the Sidoti August Virtual Investor Conference on Thursday, August 15, 2024, at 10:45 a.m. ET (7:45 a.m. PT).

Who will be presenting for Gyre Therapeutics (GYRE) at the Sidoti conference?

Han Ying, PhD, the Chief Executive Officer of Gyre Therapeutics, will be presenting a company overview at the Sidoti August Virtual Investor Conference.

How can I watch Gyre Therapeutics' (GYRE) presentation at the Sidoti conference?

You can register in advance for the presentation webcast through the link provided by Gyre Therapeutics. A replay will also be available on the Events and Presentations page of Gyre's website after the live session.

What is the focus of Gyre Therapeutics' (GYRE) clinical development programs?

Gyre Therapeutics (GYRE) focuses its clinical development programs on a variety of chronic organ diseases.